参考文献/References:
［1］Leitao J, HAN Guang-ming, Lee LX, et al. Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk ［J］. Am J Obstet Gynecol, 2010, 203(4): e1-e6.
［2］Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40 ［J］. Obstet Gynecol, 1997, 90 (3): 434-440.
［3］Kaku T, Yoshikawa H, Kamura T, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women:central pathologic review and treatment outcome ［J］. Cancer Lett, 2001, 167(1): 39-48.
［4］Jy P, Kim DY, Kim JH, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer(KGOG2002)［J］. Eur J Cancer, 2013, 49 (4): 868-874.
［5］高祖标，吴妍，蔡丹丹．甲羟孕酮对年轻子宫内膜不典型增生患者的疗效研究 ［J］．实用癌症杂志，2013，28 （3）：266-268．
［6］Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women ［J］. Journal of Clinical Oncology, 2007, 25 (19): 2798-2803.
［7］Zq S, ZHU H-t, LIN J-f, et al. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives ［J］. Obstet Gynecol, 2008, 112(2): 465-467.
［8］XIE Ya, WANG Yan-ling, YU Li, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells ［J］. J Steroid Biochem Mol Biol, 2011, 126(3/5): 113-120.
［9］Mitsuhashi A, Sato Y, Kiyokawa T, et al. Phase Ⅱ study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer ［J］. Ann Oncol, 2016, 27(2): 262-266.
［10］El Behery MM, Saleh HS, Ibrahiem MA, et al. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia ［J］. Reprod Sci, 2015, 22(3): 329-334.
［11］Morelli M, Di Cello A, Venturella RA, et al. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women ［J］. Gynecological Endocrinology, 2013, 29(2): 156-159.
［12］Lee SY, Kim MK, Park H, et al. The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women［J］. J Gynecol Oncol, 2010, 21(2): 102-105.
［13］Orbo A, Vereide A, Arnes M, et al. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia:a national multicentre randomised trial［J］. BJOG, 2014, 121(4): 477-486.
［14］Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis ［J］. Am J Obstet Gynecol, 2012, 207(4): 266.e1-266.12.
［15］Gallos ID, Krishan P, Shehmar M, et al. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study ［J］. Hum Reprod, 2013, 28(11): 2966-2971.
［16］张晴晴，蒋凤艳．促性腺激素释放激素激动剂在女性患者中的临床应用进展 ［J］．医学综述，2013，19（15）：2710-2712．
［17］Agorastos T, Bontis J, Vakiani A, et al. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data［J］. Gynecol Oncol, 1997, 65 (1): 102-114.
［18］宋宁，程迪，马晓欣，等．GnRH-a 对子宫内膜非典型增生的治疗价值 ［J］．现代肿瘤医学，2015，23 （5）：686-688．
［19］张纯溪，岳慧敏，张萍，等．促性腺激素释放激素激动剂与左炔诺孕酮宫内节育器联合治疗子宫内膜不典型增生的临床疗效研究 ［J］．中国计划生育和妇产科，2016，8 （6）：56-58．
［20］Minig L, Franchi D, Boveri S, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women ［J］. Ann Oncol, 2011, 22(3): 643-649.
［21］Pashov AI, Tskhay VB, Ionouchene SV. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study［J］. Gynecological Endocrinology, 2012, 28(7): 559-561.
［22］Ichinose M, Fujimoto A, Osuga Y, et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia ［J］. International Journal of Gynecological Cancer, 2013, 23(2): 288-293.
［23］Gonthier C, Piel B, Touboul C, et al. Cancer incidence in patients with atypical endometrial hyperplasia managed by primary hysterectomy or fertility-sparing treatment ［J］. Anticancer Res, 2015, 35(12):6799-6804.
相似文献/References:
[1]张以文.绝经期激素治疗中不同孕激素制剂的比较[J].中国计划生育和妇产科,2012,(05):0.
ZHANG Yi-wen.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(9):0.
[2]何玉萍,孙家玉,李晋平,等.雌激素配伍孕激素在吸宫术后预防宫腔粘连的作用[J].中国计划生育和妇产科,2014,(07):0.
HE Yu-ping,SUN Jia-yu,LI Jin-Ping,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(9):0.
[3]王丽娜,陈映婷.封闭抗体阴性的早期流产患者使用被动免疫治疗的效果观察[J].中国计划生育和妇产科,2015,(08):0.
WANG Li-na,CHEN Ying-ting,[J].Chinese Journal of Family Planning & Gynecotokology,2015,(9):0.
[4]那晶,汤小晗,李萌,等.卵泡中肝素结合表皮生长因子的表达与卵泡发育及雌孕激素水平的关系[J].中国计划生育和妇产科,2015,(12):0.
NA Jing,TANG Xiao-han,LI Meng,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2015,(9):0.
[5]张纯溪,岳慧敏,张萍,等.促性腺激素释放激素激动剂与左炔诺孕酮宫内节育器联合治疗子宫内膜不典型增生的临床疗效研究[J].中国计划生育和妇产科,2016,(06):0.
ZHANG Chun-xi,YUE Hui-min,ZHANG Ping,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2016,(9):0.
[6]张纯溪,岳慧敏,张萍*,等.促性腺激素释放激素激动剂与左炔诺孕酮宫内节育器联合治疗子宫内膜不典型增生的临床疗效研究[J].中国计划生育和妇产科,2016,(6):56.
ZHANG Chun-xi,YUE Hui-min,ZHANG Ping*,et al.The clinical efficacy observation of GnRH-agonist and levonorgestrel-releasing intrauterine device for the treatment of endometrial hyperplasia[J].Chinese Journal of Family Planning & Gynecotokology,2016,(9):56.
[7]万琪,雷贞武*.孕激素防止流产值得关注的几个问题[J].中国计划生育和妇产科,2017,(11):1.
[8]陈静,刘彩霞*.双胎妊娠抗早产临床预测及措施[J].中国计划生育和妇产科,2018,(11):15.
[9]周怀君.子宫内膜息肉的药物治疗新进展[J].中国计划生育和妇产科,2021,(7):33.[doi:10.3969/j.issn.1674-4020.2021.07.11]
[J].Chinese Journal of Family Planning & Gynecotokology,2021,(9):33.[doi:10.3969/j.issn.1674-4020.2021.07.11]